Primary and Secondary Outcomes Authors used national Swedish electronic health registers to identify people with diagnosed depression or anxiety who used antidiabetic medication between 20092022
They could mediate vascular remodeling by a signaling pathway, which was different from the VEGF pathway
doi: 10.1515/hmbci-2022-0105 99 HerderCBongaertsBWRathmannWHeierMKowallBKoenigWet al
The term "GLP-1 supplement" covers two fundamentally different product categories with different users, different purposes, and different evidence levels
Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, Macech M, Delivanis DA, Pupovac ID, Reimondo G, et al
A clinical trial that just began dosing patients at Johns Hopkins is testing something the diabetes world has suspected for years: that the same class of drugs millions of people take to manage blood sugar may be quietly protecting the brain from shrinking